Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735083 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
A Phase 1 study of Advanced Lymphoid Leukemia, sponsored by Institut de Recherches Internationales Servier.
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 16
- Study locations
NCT02735083: Active Phase 1 study of Advanced Lymphoid Leukemia, sponsored by Institut de Recherches Internationales Servier.
NCT02735083 is a Phase 1 study of Advanced Lymphoid Leukemia that is active but no longer recruiting, run by Institut de Recherches Internationales Servier. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). The trial reports 16 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02735083, a Phase 1 study of Advanced Lymphoid Leukemia, is active but no longer recruiting, sponsored by Institut de Recherches Internationales Servier.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of UCART19 administration to patients with advanced lymphoid leukemia.
Primary Outcome
* Number, duration, outcome of all adverse events (AE) within 12 months post last UCART19 infusion * Number, duration, outcome of adverse events of special interest (AESI) up to the end of the study * Proportion of patients with adverse events leading to death up to the end of the study * For paediatric patients: assesment of the potential impact on growth curve and puberty
Conditions Studied
Interventions
- BIOLOGICAL UCART19 follow-up
Study Locations (16)
Other
- Hôpital Saint-Louis - Paris
- Hôpital Robert-Debré - Paris
- Hôpital Saint-Antoine - Paris
- Kyushyu University Hospital - Fukuoka
- Hokkaido University Hospital - Sapporo
- Hospital San Juan De Dios - Barcelona
- King's College Hospital NHS Foundation Trust - London
- UCL Great Ormond Hospital - London
- The Christie NHS Foundation Trust - Manchester
Texas
- University of Texas Southwestern Medical Center - Dallas
- University of Texas MD Anderson Cancer Center - Houston
California
- Children's Hospital Los Angeles - Los Angeles
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Moffit Cancer Center - Tampa
Massachusetts
- Massachussetts General Hospital - Charlestown
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
What the registry record for NCT02735083 still lists
NCT02735083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Advanced Lymphoid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which UCART19 follow-up is the first listed.
NCT02735083 lists 16 locations in 7 states (Other, Texas, California).
Frequently Asked Questions
What is clinical trial NCT02735083 about?
NCT02735083 is a clinical study titled "A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19". The purpose of this study is to evaluate the long-term safety and efficacy of UCART19 administration to patients with advanced lymphoid leukemia.
What is the current status of trial NCT02735083?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2021-03-10. Estimated completion is 2028-09.
What conditions does trial NCT02735083 study?
This clinical trial studies the following conditions: Advanced Lymphoid Leukemia.
What interventions are being tested in trial NCT02735083?
The interventions under investigation include: UCART19 follow-up (BIOLOGICAL).
Who is sponsoring clinical trial NCT02735083?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02735083 being conducted?
This trial has 16 study locations across California, Colorado, Florida, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02735083's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI